A life-immunotherapy medicine against lung cancer is now available for Norwegian patients.
Decision Forum for new methods decided Monday that the cancer drug pembrolizumab can be used in Norwegian hospitals, reports TV2 News.
The treatment has been approved for use in this country, but the authorities think it was too expensive.
More and more patients have paid the processing themselves, or have the cost covered by private health insurance.
At the meeting in the Decision Forum Monday, the four directors of health regions concluded that the drug can be approved.
Patients with non-small cell lung cancer can on average prolong life by six months.
Source: NTB scanpix / Norway Today